Back to Search
Start Over
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma : a subgroup analysis of a phase 2 study
- Source :
- Haematologica, Haematologica, Ferrata Storti Foundation, 2017, 102 (4), pp.e156-e159. ⟨10.3324/haematol.2016.151738⟩
- Publication Year :
- 2017
-
Abstract
- Approximately 20% of all non-Hodgkin lymphoma (NHL) and 60% of indolent NHL (iNHL) cases are follicular lymphoma (FL),[1][1],[2][2] a disease considered treatable, but not curable, with currently available therapeutic options.[3][3] While survival in patients with FL has improved with the
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Pathology
Lymphoma
Patients
analysis
Follicular lymphoma
Phases of clinical research
[SDV.CAN]Life Sciences [q-bio]/Cancer
Subgroup analysis
Medical Oncology
Time
03 medical and health sciences
0302 clinical medicine
immune system diseases
Germany
hemic and lymphatic diseases
Internal medicine
medicine
Online Only Articles
ComputingMilieux_MISCELLANEOUS
Hematology
business.industry
medicine.disease
3. Good health
030104 developmental biology
Italy
030220 oncology & carcinogenesis
Medicine
Rituximab
France
Refractory Follicular Lymphoma
business
Idelalisib
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 03906078 and 15928721
- Database :
- OpenAIRE
- Journal :
- Haematologica, Haematologica, Ferrata Storti Foundation, 2017, 102 (4), pp.e156-e159. ⟨10.3324/haematol.2016.151738⟩
- Accession number :
- edsair.doi.dedup.....506e68755679b39063547218b4074798